#TKIs
Healthy volunteers in anticancer drug development? For targeted agents like TKIs, it can speed timelines and de-risk programs. Get the safety essentials + case studies on November 10 in a Celerion webinar. https://bit.ly/4eyrJUA #ASCPTwebinar #DrugDevelopment
November 4, 2026 at 4:30 PM
Could tyrosine kinase inhibitors (TKIs) offer a promising treatment approach for metastatic PPGLs?

Xiaowen Xu et al. evaluate the efficacy & safety of different TKIs in metastatic PPGLs, examining outcomes across genetic subgroups.

🔗 doi.org/10.1530/ERC-26-0201
November 3, 2026 at 9:28 AM
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China www.thelancet.com/journals/lan...
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU...
In participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR TKIs, iza-bren significantly prolonged progression-free survival, although treatment-related ad...
www.thelancet.com
October 30, 2026 at 11:10 AM
A first-in-class bispecific ADC nearly doubled PFS compared with chemotherapy in patients with EGFR-mutated advanced NSCLC who progressed on third-generation EGFR TKIs, a phase III trial from China showed. #ESMO26 https://www.medpagetoday.com/meetingcoverage/esmo/123631
Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer
Izalontamab brengitecan nearly doubled PFS compared with chemotherapy
www.medpagetoday.com
October 28, 2026 at 10:20 PM
Tkis UT erasure is unconscienable.
October 26, 2026 at 12:02 AM
Tkis was confirmed by a student who lived in a nearby room. Fortunately that student owned a car and was willing to drive Dad to the station.

Dad the dashed down to the platform for the Londin train, and from the steps saw the student boarding.

Dad said to them "Don't get this one, there's […]
Original post on en.osm.town
en.osm.town
October 23, 2026 at 1:08 PM
📑A Review of #Neoadjuvant Therapy for Localized and Locally Advanced #RenalCellCarcinoma
🧑‍⚕️by Qian Qin, Isamu Tachibana et al.
📊15 citations
Link🔗 www.mdpi.com/2072-6694/17...

#preoperative #VEGFR #TKIs #RCC
October 21, 2026 at 7:16 AM
Can #radiotherapy delay lung cancer resistance?

Combining third-generation #EGFR inhibitors with radiotherapy was associated with longer median progression-free survival (13 vs. 18.1 months) in EGFR-mutated #NSCLC. @2024_HUST

#currentmedicalscience: doi.org/10.1007/s115...
October 16, 2026 at 1:02 PM
Such a clean pearl: optimize the dose before changing the drug. Trainees often switch TKIs at the first side effect, and this lays out why dose reduction can keep the molecular response.
October 15, 2026 at 7:10 PM
「なんで終わりにしてくんねえの」
「なんで終わりにしたいんだ」
「っどうせいつか飽きんだろ、だったら今がいい、今、終わりにしろよ」
いつかくる終わりに怯え続けるのはもう疲れた。自分だけが好きみたいで、頭の中はいつでもtkisのことばかり考えて、だからいつか失ってしまったらどう生きていけばいいかわからなくて。
tkisがいなくなったらオレはどうやって生きていけばわからないのに、きっとtkisは生きていられる。それが悔しくて苦しくて、ほっとする。

みたいな感じの付き合ってるけどなんか上手くいってない焚棪とかも書きたかったな〜
October 15, 2026 at 1:15 PM
Eski bir TKIS Blinds işçisi sendikanın “gerçekler” adı altında korku yaydığını belirterek işçilere fabrikada komiteler kurma ve birliği kendi elleriyle örme çağrısı yapıyor.
October 14, 2026 at 5:35 AM
‘Gerçekler’ diyerek korku yayan sendikacılar kimin safında? Eski bir TKIS Blinds işçisi sendikanın “gerçekler” adı altında korku yaydığını belirterek işçilere fabrikada komiteler kurma ve birliği kendi… https://www.evrensel...
‘Gerçekler’ diyerek korku yayan sendikacılar kimin safında? - Evrensel
Eski bir TKIS Blinds işçisi sendikanın “gerçekler” adı altında korku yaydığını belirterek işçilere fabrikada komiteler kurma ve birliği kendi elleriyle örme çağrısı yapıyor.
www.evrensel.net
October 13, 2026 at 9:17 PM
This weekend our Mayo Clinic leukemia group joined the comprehensive leukemia course in Las Vegas, where I spoke on chemotherapy-sparing approaches in B-ALL: immunotherapy, TKIs, and MRD-guided sequencing. @mayocliniccancer.bsky.social
October 10, 2026 at 3:45 PM
Lazertinib Plus Pemetrexed and Carboplatin in Patients With EGFR-Mutant Advanced Non-Small Cell #LungCancer after Progression on Lazertinib. www.ejcancer.com/article/S095...
Lazertinib Plus Pemetrexed and Carboplatin in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer after Progression on Lazertinib
Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether co...
www.ejcancer.com
October 9, 2026 at 9:26 AM
📢 New Review in #LiversMDPI

🧬 Vemula et al. review second- and third-line strategies after ICI failure in HCC.

🩺 TKIs remain the most widely used second-line option, while evidence for ICI rechallenge remains limited.

📖 Read More: www.mdpi.com/2673-4389/6/...

#HCC #TKIs
October 5, 2026 at 11:10 AM
Does prior systemic chemotherapy exposure influence subsequent response to ROS1 tyrosine kinase inhibitors (TKIs) in ROS1-rearranged non-small-cell lung cancer? Learn more in this #JCOPO systematic review.

Read the article. https://bit.ly/4zc5BHH

#NSCLC
October 5, 2026 at 1:00 PM
In the first of our selected abstract talks, François-Xavier Mahon demonstrates that maintaining TFR >10 years after stopping TKIs.
October 4, 2026 at 8:10 AM
Nirmalya Roy Moulik (Mumbai) and Meinolf Suttorp (Dresden) led an interactive discussion on paediatric CML, with some focus on complications including leukostasis, prescribing second-generation TKIs 💊 and issues around compliance.
October 3, 2026 at 12:30 PM
Andreas Hochhaus (Jena) opened the session with a vision for the future of trials for novel TKIs and the goals we should be aiming for in planning these studies, in addition to covering the latest available anti-CML agents.
October 3, 2026 at 2:05 PM
In the second, Massimo Breccia (Roma) and Hemant Malhotra (Jaipur) led discussions on frontline TKIs in CML, focusing on prescribing generics and TKI selection in pregnancy, amongst other topics.

#ESHCONFERENCES #CMLsm #ICMLF #HEALTHCARE #HAEMATOLOGY
October 3, 2026 at 8:41 AM
For final session of the day we had several excellent talks on a range of interesting research including immunoregulation, immunotherapy, targeting LSCs with TKIs and using immune profiles for prediction of molecular response. #ESHCML2026 #ESHCONFERENCES #CMLsm #ICMLF
October 2, 2026 at 4:46 PM
İstanbul’da Tuzla Serbest Bölgede bulunan TKİS Blinds perde fabrikasında toplu iş sözleşmesinin mürekkebi kurumadan patron işçi kıyımına başladı.3 işçi atıldı
www.evrensel.net/haber/600298...
TKİS Blinds’te imzanın mürekkebi kurumadan 3 işçi atıldı - Evrensel
İstanbul’da Tuzla Serbest Bölgede bulunan TKİS Blinds perde fabrikasında toplu iş sözleşmesinin mürekkebi kurumadan patron işçi kıyımına başladı.
www.evrensel.net
October 2, 2026 at 8:59 AM
Jane Apperley presented a fascinating journey through 25 years of TKIs for the Tessa Holyoake Memorial Lecture, covering the tremendous discovery of TKIs, the knowledge advancements that supported this, and the key contributors who drove their development. #ESHCML2026 #ESHCONFERENCES #CMLsm #ICMLF
October 2, 2026 at 9:30 AM
Ph+ ALL, one map. Frontline is the pony trolley plus the blinatumomab bus. At relapse you check ABL1 first: T315I is the iceberg that blocks most TKIs. Then CAR T, then the transplant bridge.

Make your own at meducationai.com
September 28, 2026 at 2:02 PM